KALA BIO, Inc. (KALA) stock
Close on Nov 12, 2026Market cap $3.11MP/E –Yield –
KALA BIO, Inc. reported revenue of $0 for fiscal 2025. At the latest close the market valued the company at $3.11M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.11M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.34
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$10.08M
- EPS, diluted
- -$165.50
- Book value per share
- $121.95
- Diluted shares
- 0M
Trading
- Previous close
- $0.17
- Open
- $0.17
- Day's range
- $0.16 – $0.17
- Volume
- 384,794
- Average volume (20 days)
- 199,545
- Beta (5 years)
- 0.37
- 52-week range
- $0.11 – $95.50
- RSI (14 days)
- 29.0
- Volatility (1 year)
- 135.7%
- Relative volume
- 0.34×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KALA | S&P 500 | Difference | KALA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -42.5% | -2.7% | −39.8 pts | ||
| 3 months | -81.8% | -1.7% | −80.0 pts | ||
| Year to date | -99.4% | +11.9% | −111.3 pts | ||
| 1 year | -99.6% | +12.0% | −111.5 pts | ||
| 3 years | -99.9% | +78.2% | −178.1 pts | -91.7% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -87.5% | +11.6% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kala Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Update
- News
- News
About Kala Bio
Pharmaceutical Preparations
KALA BIO, Inc. is a transitioning biopharmaceutical company that focuses on developing an on-premises artificial intelligence infrastructure platform tailored for the biotechnology and pharmaceutical sectors. Operating through its licensed Researgency platform, the company intends to provide platform-as-a-service offerings, implementation support, data analytics, and maintenance subscriptions. These tools allow biotechnology firms, pharmaceutical enterprises, and contract research organizations to analyze biological datasets, coordinate research workflows, and preserve data sovereignty within private environments. Concurrently, the company seeks to monetize its proprietary mesenchymal stem cell secretome biologics portfolio through licensing, sales, or partnerships following the discontinuation of its clinical-stage candidate KPI-012.
Company profile, executives and historyKala Bio stock: common questions
What is Kala Bio's stock price?
KALA closed at $0.16 on Nov 12, 2026, down 5.85% on the day. Over the past 52 weeks it traded between $0.11 and $95.50.
What is Kala Bio's market cap?
Kala Bio was worth $3.11M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KALA's P/E ratio?
Kala Bio lost money over fiscal 2025 (diluted EPS -$165.50), so it has no meaningful P/E ratio.
How much revenue does Kala Bio make?
Kala Bio reported revenue of $0 for fiscal 2025.
Does Kala Bio pay a dividend?
No. Kala Bio has not paid a cash dividend over the last twelve months.
How has KALA stock performed over the past year?
Including dividends, KALA returned -99.6% over the past year, against +12.0% for the S&P 500.
Who are Kala Bio's competitors?
Companies most similar to Kala Bio by business, industry and size include SHPH, CDT, PLRX, OCS, IBIO.
See a number that looks wrong?